Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Plant Signal Behav ; 18(1): 2213937, 2023 12 31.
Artigo em Inglês | MEDLINE | ID: mdl-37204036

RESUMO

Fatty acid biosynthesis 2 (FAB2) is an essential enzyme responsible for the synthesis of unsaturated fatty acids in chloroplast membrane lipids found in leaves and triacylglycerols (TAG) in seeds. FAB2 functions at the junction of saturated to unsaturated fatty acid conversion in chloroplasts by converting 18:0-ACP to 18:1-ACP. In the present study, plant growth and seed phenotypes were examined in three Arabidopsis T-DNA mutants (fab2-1, fab2-2, and fab2-3). The three fab2 T-DNA mutants exhibited increased 18:0 fatty acid content in both the leaves and seeds. The degree of growth inhibition of the fab2 mutant was proportional to the increase in 18:0 and decrease in 18:3 fatty acids present in the leaves. The FAB2 mutation affected seed yield but not the seed phenotype. This result indicates that FAB2 affects the fatty acid composition of the leaf chloroplast membrane more than seed TAG. In summary, the characteristics of these three fab2 mutants provide information for studying leaf membrane lipid and seed oil biosynthesis.


Assuntos
Proteínas de Arabidopsis , Arabidopsis , Ácidos Graxos Dessaturases , Arabidopsis/metabolismo , Proteínas de Arabidopsis/genética , Proteínas de Arabidopsis/metabolismo , Ácidos Graxos , Ácidos Graxos Insaturados , Regulação da Expressão Gênica de Plantas , Lipídeos de Membrana , Fenótipo , Óleos de Plantas , Sementes/metabolismo , Ácidos Graxos Dessaturases/genética , Ácidos Graxos Dessaturases/metabolismo
2.
BMC Complement Altern Med ; 18(1): 295, 2018 Nov 06.
Artigo em Inglês | MEDLINE | ID: mdl-30400922

RESUMO

BACKGROUND: Extracellular polymeric substances isolated from Aureobasidium pullulans (EAP), containing specifically 13% ß-1,3/1,6-glucan, have shown various favorable bone-preserving effects. Textoria morbifera Nakai (TM) tree has been used as an ingredient in traditional medicine and tea for various pharmacological purposes. Thus, the present study was aimed to examine the synergistic anti-osteoporotic potential of mixtures containing different proportions of EAP and TM compared with that of the single formulations of each herbal extract using bilateral ovariectomized (OVX) mice, a renowned rodent model for studying human osteoporosis. METHODS: Thirty five days after bilateral-OVX surgery, 9 combinations of EAP:TM (ratios = 1:1, 1:3, 1:5, 1:7, 1:9, 3:1, 5:1, 7:1, 9:1) and single separate formulations of EAP or TM were supplied orally, once a day for 35 days at a final concentration of 200 mg/kg. Variations in body weight gains during the experimental periods, as well as femur weights, bone mineral density (BMD), bone strength (failure load), and mineral content (calcium [Ca] and inorganic phosphorus [IP]) following sacrifice were measured. Furthermore, histomorphometric and histological profile analyses of serum biochemical parameters (osteocalcin content and bone specific alkaline phosphatase [bALP] activity) were conducted following sacrifice. Femurs histomorphometric analyses were also conducted for bone resorption, structure and mass. The results for the mixed formulations of EAP:TM and separate formulations were compared with those of risedronate sodium (RES). RESULTS: The EAP:TM (3:1) formulation synergistically enhanced the anti-osteoporotic potential of individual EAP or TM formulations, possibly due to enhanced variety of the active ingredients. Furthermore, the effects of EAP:TM were comparable to those of RES (2.5 mg/kg) treatment. CONCLUSION: The results of this study suggest that, the EAP:TM (3:1) combination might act as a new pharmaceutical agent and/or health functional food substance for curing osteoporosis in menopausal women.


Assuntos
Araliaceae/química , Ascomicetos/química , Produtos Biológicos/farmacologia , Conservadores da Densidade Óssea/farmacologia , Densidade Óssea/efeitos dos fármacos , Animais , Modelos Animais de Doenças , Matriz Extracelular de Substâncias Poliméricas/química , Feminino , Fêmur/efeitos dos fármacos , Fêmur/patologia , Camundongos , Osteoporose/patologia , Ovariectomia
3.
Comp Med ; 67(2): 157-164, 2017 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-28381316

RESUMO

Diarrheal disease is the second leading cause of death in children younger than 5 y, and the most common cause of acute watery diarrhea in young children worldwide is rotaviral infection. Medicines to specifically reduce diarrhea would be a desirable adjunctive treatment to supportive fluid therapy to decrease the mortality rate of diarrheal diseases. In this study, we evaluated the efficacy of an antisecretory drug, racecadotril, in treating human rotavirus (HRV)-induced diarrhea in a neonatal gnotobiotic pig model. In total, 27 gnotobiotic pigs were randomly assigned (n = 9 per group) to receive either racecadotril, chlorpromazine (positive-control drug), or PBS (mock treatment) after inoculation with HRV. Pigs were weighed daily and rectal swabs were collected to determine fecal consistency scores and virus shedding. Rotaviral infection was confirmed by ELISA and cell culture immunofluorescence. Overall, the racecadotril-treated pigs had less severe illness than either the chlorpromazine- or mock-treated groups; this conclusion was supported by the lower fecal-consistency scores, shorter duration of diarrhea, and significant gain in body weight during the course of the study of the racecadotril-treated pigs. Through its influence on decreasing intestinal hypersecretion, racecadotril was better able to control the clinical signs of rotaviral infection in the gnotobiotic pigs. These results lend support for using racecadotril as a treatment for rotaviral diarrhea.


Assuntos
Antidiarreicos/uso terapêutico , Diarreia/tratamento farmacológico , Infecções por Rotavirus/tratamento farmacológico , Tiorfano/análogos & derivados , Animais , Diarreia/virologia , Avaliação Pré-Clínica de Medicamentos , Rotavirus , Sus scrofa , Tiorfano/uso terapêutico , Redução de Peso/efeitos dos fármacos
4.
J Control Release ; 140(1): 55-60, 2009 Nov 16.
Artigo em Inglês | MEDLINE | ID: mdl-19616596

RESUMO

Immunoliposomes directed by monoclonal antibodies are promising vehicles for tumor targeted drug delivery. Development of a long-circulating formulation of pH-sensitive liposomes (PSLs) with epidermal growth factor receptor (EGFR) antibody attached was designed and tested using A549 cells and BALB/c-nu/nu mouse tumor model. PSL formulation was prepared using small unilamellar vesicles of DOPE and CHEMS (6:4 molar ratio) by REV method. The average size and zeta-potential of the formulation measured by dynamic laser-light scattering were approximately 146+/-43.9 nm (PDI=0.09+/-0.02) and -1.77+/-0.03 mV, respectively. A549 cells were xenotransplanted into BALB/c-nu/nu mice and various formulations of gemcitabine (gem), such as in its free form, PSLs or Ab-PSLs, were injected intravenously via a tail vein. The rate of tumor volume increment in Ab-PSLs with gem-treated group was remarkably slower than that of other drug-treated group. The tumor from Ab-PSLs with gem 160 mg/kg-injected group exhibited a markedly lowest account of PCNA labeled cells and had highest TUNEL-positive cells among tested. This suggests that treatment of Ab-PSLs with gem resulted in an increased apoptosis of tumor cells, leading to tumor growth inhibition. These results demonstrate that PSLs provide an efficient and targeted delivery of gemcitabine and may represent a useful new treatment approach for tumors which overexpress the EGFR.


Assuntos
Antimetabólitos Antineoplásicos/farmacologia , Desoxicitidina/análogos & derivados , Receptores ErbB/metabolismo , Lipossomos/farmacologia , Neoplasias Pulmonares/tratamento farmacológico , Animais , Apoptose/efeitos dos fármacos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Linhagem Celular Tumoral , Desoxicitidina/farmacologia , Avaliação Pré-Clínica de Medicamentos , Receptores ErbB/imunologia , Humanos , Concentração de Íons de Hidrogênio , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas/métodos , Camundongos , Camundongos Nus , Transplante de Neoplasias , Tamanho da Partícula , Antígeno Nuclear de Célula em Proliferação/metabolismo , Distribuição Aleatória , Carga Tumoral/efeitos dos fármacos , Ensaios Antitumorais Modelo de Xenoenxerto/métodos , Gencitabina
5.
J Vet Intern Med ; 18(4): 545-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15320596

RESUMO

The effect of corn oil (approximately 60% [wt/vol] linoleic acid) dietary supplementation on various components of equine gastric secretion was studied by use of a repeated-measures experimental design. Four healthy adult ponies were surgically fitted with gastric cannulas. The ponies were then fed a free-choice hay diet for 5 weeks, which was followed by 5 weeks of the same diet supplemented with 45 mL of corn oil daily. Gastric contents were analyzed under basal and pentagastrin-stimulated conditions once weekly during the latter 2 weeks on each diet. Gastric contents were collected at 30-minute intervals, and volume, hydrogen ion concentration, sodium content, and prostaglandin E2 (PGE2) content were measured. Data were analyzed by a linear fixed-effect modeling procedure. During the diet supplemented with corn oil, the ponies had, under basal and pentagastrin-stimulated conditions, significantly decreased acid output and significantly increased PGE2 and sodium outputs compared to those measured before corn oil supplementation. We conclude that corn oil supplementation may be an effective and inexpensive way to increase the protective properties of equine glandular gastric mucosa. This could be particularly helpful in reducing the chances of ulceration associated with nonsteroidal anti-inflammatory drug (NSAID) administration.


Assuntos
Óleo de Milho/administração & dosagem , Suplementos Nutricionais , Mucosa Gástrica/efeitos dos fármacos , Fármacos Gastrointestinais/farmacologia , Doenças dos Cavalos/prevenção & controle , Pentagastrina/farmacologia , Úlcera Gástrica/veterinária , Animais , Dinoprostona/metabolismo , Feminino , Ácido Gástrico/metabolismo , Suco Gástrico/efeitos dos fármacos , Suco Gástrico/metabolismo , Mucosa Gástrica/metabolismo , Fármacos Gastrointestinais/administração & dosagem , Cavalos , Masculino , Pentagastrina/administração & dosagem , Sódio/metabolismo , Úlcera Gástrica/prevenção & controle
6.
Stud Health Technol Inform ; 85: 89-95, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-15458066

RESUMO

Attention Deficit Hyperactivity Disorder (ADHD) is a childhood syndrome characterized by short attention span, impulsiveness, and hyperactivity, which often leads to learning disabilities and various behavioral problems. The prevalence rates for ADHD varied from a low of 2.0% to a high of 6.3% in 1992 statistics, and it may be higher now. Using Virtual Environments and Neurofeedback, we have developed an Attention Enhancement System for treating ADHD. And we made a clinical test. Classroom-based virtual environments are constructed for intimacy and intensive attention enhancement. In this basic virtual environment, subjects performed some training sessions. There are two kinds of training sessions. One is Virtual Reality Cognitive Training (VRCT) and the other is Virtual Reality Neurofeedback Training (VRNT). In VRNT, we made a change in the virtual environment by Neurofeedback. Namely, if the Beta ratio is greater than the specified threshold level, the change as positive reinforce is created in the virtual environment. 50 subjects, aged 14 to 18, who had committed crimes and had been isolated in a reformatory took part in this study. They were randomly assigned to one of five 10-subject groups: a control Group, two placebo groups, and two experimental groups. The experimental groups and the placebo groups underwent 10 sessions over two weeks. The control group underwent no training session during the same period of time. While the experimental groups used HMD and Head Tracker in each session, the placebo groups used only a computer monitor. Consequently, only the experimental Groups could look around the virtual classroom. Besides that, Placebo Group 1 and Experimental Group 1 performed the same task(Neurofeedback Training), and Placebo Group 2 and Experimental Group 2 also performed the same task(Cognitive Training). All subjects Continuous Performance Task(CPT) before and after all training sessions. In the number of correct answers, omission errors and signal detection index (d'), the subjects' scores from CPT showed significant improvement (p<0.01) after all of the training sessions, while control group indicated no significant change. And experimental groups showed significant difference (p<0.01) with placebo groups. Lastly, the Virtual Reality Neurofeedback training group and the Virtual Reality Cognitive training group indicated not significant difference. Our System is supposed to enhance subjects' attention and lead their behavioral improvement. And also, we can conclude that virtual reality training (both Neurofeedback training and Cognitive training) has an advantage for attention enhancement compared with desk-top training.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/terapia , Atenção , Terapia Assistida por Computador/instrumentação , Interface Usuário-Computador , Adolescente , Ritmo beta , Biorretroalimentação Psicológica/instrumentação , Eletroencefalografia/instrumentação , Desenho de Equipamento , Feminino , Análise de Fourier , Humanos , Masculino , Processamento de Sinais Assistido por Computador/instrumentação , Meio Social
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA